feed,title,long_url,short_url
Benzinga,10-Year Phase 3 Trial Shows CEL-SCI's Multikine immunotherapy Extends Lives In Head & Neck Cancer Patients,https://benzinga.com/general/biotech/22/11/29826350/10-year-phase-3-trial-shows-cel-scis-multikine-immunotherapy-extends-lives-in-head-neck-cancer-pa,https://bit.ly/3ETYc6n
